GARDASIL 9 sol inj 30 µg 10 pce

7680653870026 CH-65387 J07BM03 08.08.
GARDASIL 9 sol inj 30 µg 10 pce
Fiches Amavita / Sun Store / Coop Vitality

Details

Product number
6538701
CPT
-
Packaging group
10
Unit
Fertigspritze(n)
Composition
proteinum L1 papillomaviri humani typus 6 30 µg, proteinum L1 papillomaviri humani typus 11 40 µg, proteinum L1 papillomaviri humani typus 16 60 µg, proteinum L1 papillomaviri humani typus 18 40 µg, proteinum L1 papillomaviri humani typus 31 20 µg, proteinum L1 papillomaviri humani typus 33 20 µg, proteinum L1 papillomaviri humani typus 45 20 µg, proteinum L1 papillomaviri humani typus 52 20 µg, proteinum L1 papillomaviri humani typus 58 20 µg, aluminium ut aluminii hydroxyphosphas sulfas amorphus, natrii chloridum, histidinum, polysorbatum 80, natrii boras, aqua ad iniectabile ad suspensionem pro 0.5 ml corresp. natrium 3.78 mg.

Articles (1)

Gardasil 9, Injektionssuspension in Fertigspritze
Injektionssuspension
10
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
04/07/2026
Professional SmPC
Français
04/07/2026
Professional SmPC
Italien
04/07/2026

Detailed composition

Substance Quantity Type Category
proteinum L1 papillomaviri humani typus 6
30.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 11
40.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 16
60.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 18
40.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 31
20.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 33
20.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 45
20.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 52
20.0 UG Substance Wirkstoff (Principe actif)
proteinum L1 papillomaviri humani typus 58
20.0 UG Substance Wirkstoff (Principe actif)
aluminium
- Substance HNIDK
aluminii hydroxyphosphas sulfas amorphus
- Substance HNIDK
natrii chloridum
- Substance HNIDK
histidinum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
natrii boras
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
3.78 MG Substance HBESI

Authorization holder

MSD Merck Sharp & Dohme AG

6005 Luzern

Authorization information

Swissmedic authorization number
65387
Drug name
Gardasil 9, Injektionssuspension in Fertigspritze
Galenic form
INJFS
ATC Code
J07BM03
Authorization status
Z
Dispensation category
B
First authorization
29/07/2016
Authorization expiration date
31/12/9999
IT number
08.08.
Domain
Human medicine
Field of application
Humaner Papillomavirus-Impfstoff (Typen 6, 11, 16, 18, 31, 33, 45, 52, 58)

Packaging details

Description (FR)
GARDASIL 9 sol inj 30 µg 10 pce
Description (DE)
GARDASIL 9 Inj Lös 30 µg 10 Stk
Market launch
29/07/2016
Narcotic (BTM)
No

Other packaging sizes

GARDASIL 9 sol inj 30 µg 1 pce
1 FESP
View
Buy us a coffee Explore the data